寶沙發展(01069.HK)夥深圳佳仕森共建人蔘品牌 料第四季試營運
寶沙發展(01069.HK)表示,就早前公佈與深圳佳仕森達成戰略合作,雙方就擬發展的人蔘品種及等級、種植及加工方法以及該業務發展的預期時間表進行討論,計劃就生產的西洋參共同建立品牌,並擬於今年第四季開始業務試營運。
試營運期間,雙方將建立一條生產線,所生產西洋參的品質將由經認證實驗室定期進行檢測,生產線將適時進行微調以確保所生產的西洋參等級達到標準。
公司預期,一旦生產線完全建成,能生產穩定品質及數量的西洋參以供消費後,雙方亦可考慮利用西洋參開發其他保健品及副產品,如中草藥飲料、人蔘酒、護膚品及化妝品。(gc/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.